Flavonoid compounds: A review of anticancer properties and interactions with cis-diamminedichloroplatinum(II)

被引:69
|
作者
Kosmider, B [1 ]
Osiecka, R [1 ]
机构
[1] Univ Lodz, Dept Cytogenet & Plant Mol Biol, PL-90237 Lodz, Poland
关键词
flavonoid compounds; cis-DDPI; anticancer properties; interactions;
D O I
10.1002/ddr.10421
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Flavonoid compounds, especially quercetin and genistein, have antitumor activity. These compounds are cytotoxic to cancer cells but have no or insignificant activity in. normal cells., These beneficial properties prompted synthesis of flavonoid synthetic derivatives, e.g., flavopiridol; 5-amino-2,3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one; B43-genistein and EGF-genistein). cis-DDP (cis-diamminedichloroplatinum(II)) is one of the most effective drugs used for chemotherapy, but its actions are limited by many side effects. Beneficial synergistic effects of flavonoids (e.g., quercetin, genistein, butein, tannic acid) and cis-DDP were found in cis-DDP-sensitive and resistant cancer cells that resulted in a lower toxicity for, cis-DDP. Further studies focused on the synthesis of complexes of compounds belonging to different groups, e.g., cis-bis(3-aminoflavone)dichloroplatinum(II) where introduction of the flavone ligand altered the DNA-binding properties of the complex as compared to cis-DDP alone. The beneficial anticancer and antioxidant properties of flavonoids and their synthetic derivatives have prompted further research on the synergistic interactions of these compounds with routinely applied chemotherapeutic drugs, e.g. cis-DDP. (c) 2004 Wiley-Liss, Inc.
引用
收藏
页码:200 / 211
页数:12
相关论文
共 50 条
  • [31] CIS-DIAMMINEDICHLOROPLATINUM (II) OTOTOXICITY IN THE GUINEA-PIG
    ESTREM, SA
    BABIN, RW
    MOORE, KC
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1981, 89 (04) : 638 - 645
  • [32] SODIUM THIOSULFATE INHIBITS CIS-DIAMMINEDICHLOROPLATINUM(II) ACTIVITY
    UOZUMI, J
    ISHIZAWA, M
    IWAMOTO, Y
    BABA, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1984, 13 (02) : 82 - 85
  • [33] SELECTIVE REDUCTION OF CIS-DIAMMINEDICHLOROPLATINUM(II) NEPHROTOXICITY BY EBSELEN
    BALDEW, GS
    MCVIE, JG
    VANDERVALK, MA
    LOS, G
    DEGOEIJ, JJM
    VERMEULEN, NPE
    CANCER RESEARCH, 1990, 50 (21) : 7031 - 7036
  • [34] ENHANCEMENT OF THE ANTIPROLIFERATIVE ACTIVITY OF CIS-DIAMMINEDICHLOROPLATINUM(II) BY QUERCETIN
    HOFMANN, J
    FIEBIG, HH
    WINTERHALTER, BR
    BERGER, DP
    GRUNICKE, H
    INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (03) : 536 - 539
  • [35] INACTIVATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) IN BLOOD BY SODIUM THIOSULFATE
    ABE, R
    AKIYOSHI, T
    BABA, T
    ONCOLOGY, 1990, 47 (01) : 65 - 69
  • [36] EVALUATION OF CIS-DIAMMINEDICHLOROPLATINUM (II) (CISPLATIN) NEUROTOXICITY IN RATS
    DEKONING, P
    NEIJT, JP
    JENNEKENS, FGI
    GISPEN, WH
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 89 (01) : 81 - 87
  • [37] INHIBITION OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE BY CIS-DIAMMINEDICHLOROPLATINUM(II)
    CHIU, CSM
    CHAN, AK
    WRIGHT, JA
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1992, 70 (12): : 1332 - 1338
  • [38] INTERACTION OF CIS-DIAMMINEDICHLOROPLATINUM(II) WITH MITOCHONDRIAL PHOSPHATE CARRIER
    TKACOVA, E
    KUZELA, S
    NEOPLASMA, 1985, 32 (06) : 679 - 683
  • [39] COMPLEXING OF ACTIN AND OTHER NUCLEAR PROTEINS TO DNA BY CIS-DIAMMINEDICHLOROPLATINUM(II) AND CHROMIUM COMPOUNDS
    MILLER, CA
    COHEN, MD
    COSTA, M
    CARCINOGENESIS, 1991, 12 (02) : 269 - 276
  • [40] CLINICAL AND PHARMACOLOGICAL STUDIES WITH CIS-DIAMMINEDICHLOROPLATINUM (II) (CIS-PT)
    DECONTI, RC
    LANGE, RC
    CREASEY, WA
    HARDER, HC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1972, 13 (MAR): : 96 - &